Singapore markets closed

BCRX Jan 2023 11.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
3.80000.0000 (0.00%)
As of 03:57PM EDT. Market open.
Full screen
Previous close3.8000
Open3.7000
Bid2.8000
Ask3.2000
Strike11.00
Expiry date2023-01-20
Day's range3.7000 - 3.8000
Contract rangeN/A
Volume4
Open interest4
  • Motley Fool

    BioCryst Pharmaceuticals (BCRX) Q2 2022 Earnings Call Transcript

    At this time, [Operator instructions] I will now turn the call over to your host, Mr. John Bluth at BioCryst. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; chief medical officer, Dr.

  • Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

    Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover here appears to be the news that the Food and Drug Administration (FDA) has lifted the partial clinical hold on BCX9930. BCX9930 is an oral Factor D inhibitor indicated for a rare blood disease known as paroxysmal nocturnal hemoglobinuria (PNH).

  • Zacks

    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

    BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?